U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296328) titled 'Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter' on Dec. 18.
Brief Summary: This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted therapy for improving clinical outcomes in individuals who stutter, is warranted. The aims of this study include:
* Aim 1: Assess the safety and feasibility of ps...